03 March 2023 | News
DanausGT has established multiple R&D pipelines, and Porton Advanced will offer gene and cell therapy CDMO solutions
Image credit: prnewswire
China-based startups Porton Advanced Solutions and DanausGT Biotechnology have announced a strategic collaboration in gene and cell therapy pipelines to expedite the development of innovative therapeutics.
As an end-to-end gene and cell therapy service provider, Porton Advanced CDMO offers comprehensive solutions covering plasmids, cell therapy, gene therapy, oncolytic virus, mRNA therapy, and bacterial therapy.
On the other hand, DanausGT focuses on researching, developing, and producing new anti-cancer drugs and rare diseases with gene editing technology. DanausGT has established multiple R&D pipelines, and Porton Advanced will offer gene and cell therapy CDMO (contract development and manufacturing) solutions to DanausGT, including plasmid, virus, and cell therapy products.
"hrough our end-to-end gene and cell therapy CDMO, we hope to help DanausGT achieve IND approval for multiple pipelines and advance the development pipeline from domestic and overseas into the clinical stage. This collaboration will accelerate the development of innovative CGT therapeutics," said Dr Wang Yangzhou, CEO of Porton Advanced.